[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355606-105":59,"doc-detail-355606-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncofetal-reprogramming-in-hepatocellular-carcinoma-linking-developmental-programs-to-cancer-vaccines-and-immunotherapy","Oncofetal reprogramming in hepatocellular carcinoma - linking developmental programs to cancer vaccines and immunotherapy","","Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality and is shaped by tumour-intrinsic heterogeneity and an immunosuppressive tumour microenvironment. Tumours can reactivate developmental programs, forming an oncofetal ecosystem marked by foetal antigens and foetal-like stromal and immune subsets that drive immune evasion and influence therapy response. This review summarizes mechanisms of oncofetal reprogramming across tumour, stromal, and immune compartments and evaluates vaccine and immunotherapy strategies, including mRNA–lipid nanoparticle platforms and rational combinations with checkpoint inhibitors, addressing liver tolerance and antigenic heterogeneity.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncofetal-reprogramming-in-hepatocellular-carcinoma-linking-developmental-programs-to-cancer-vaccines-and-immunotherapy/355606/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncofetal-reprogramming-in-hepatocellular-carcinoma-linking-developmental-programs-to-cancer-vaccines-and-immunotherapy/355606.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is oncofetal reprogramming in hepatocellular carcinoma?","Question",{"text":112,"@type":113},"HCC tumours can reactivate developmental programs, creating an oncofetal ecosystem characterized by re-expression of foetal antigens and foetal-like stromal and immune subsets.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the oncofetal ecosystem affect immunotherapy outcomes?",{"text":117,"@type":113},"Oncofetal features promote immune evasion and shape therapeutic response in the clinic, contributing to variability in immunotherapy effectiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"Which vaccine approaches are highlighted as promising in this review?",{"text":121,"@type":113},"The review highlights emerging vaccine platforms, with a particular emphasis on mRNA–lipid nanoparticle vaccines designed to induce robust, durable antitumour immunity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355606,1790316155,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","pISSN 2287-2728 eISSN 2287-285X  \nReview  \n[https://doi.org/10.3350/cmh.2025.1410](https://doi.org/10.3350/cmh.2025.1410)[ ](https://doi.org/10.3350/cmh.2025.1410)Clinical and Molecular Hepatology 2026;32:620-645  \nOncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy  \nDayangku Nordiyana B. P. Hassanel1,2 and Ankur Sharma1,2,3  \n1Translational Genomics Program, Garvan Institute of Medical Research; 2St. Vincent’s Clinical School, Faculty of Medicine and Health, University of New South Wales, Darlinghurst, Australia; 3KK Research Centre, KK Women’s and Children’s Hospital, Singapore  \nHepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer mortality worldwide. Its pathogenesis reflects a combination of tumour-intrinsic heterogeneity and a profoundly immunosuppressive tumour microenvironment. Growing evidence shows that tumours recapitulate developmental programs to establish an oncofetal ecosystem, characterised by the re-expression of foetal antigens and foetal-like stromal and immune subsets. These features drive immune evasion and shape therapeutic response, contributing to immunotherapy outcomes in clinic. This review outlines mechanistic insights into oncofetal reprogramming across tumour, stromal, and immune compartments and evaluates therapeutic strategies that target these dependencies. We highlight emerging vaccine platforms, cellular therapies, and biologics targeting oncofetal antigens, with particular emphasis on mRNA–lipid nanoparticle vaccines and their potential to induce robust, durable antitumour immunity. We further discuss rational combinatorial strategies that integrate vaccines with immune checkpoint inhibitors. Finally, we discuss how overcoming liver tolerance and antigenic heterogeneity will be essential for effective oncofetal-directed therapies. Collectively, targeting the oncofetal ecosystem through coordinated vaccine, cellular, and immunotherapeutic strategies offers a path toward more durable responses and broader immunotherapy benefits in HCC. (Clin Mol Hepatol 2026;32:620-645)  \nKeywords: Hepatocellular carcinoma; Oncofetal reprogramming; mRNA therapeutics; Vaccines; Immunotherapy  \nINTRODUCTION  \nHepatocellular carcinoma (HCC) remains a major global health challenge and represents the most common primary malignancy of the liver, characterised by high morbidity and mortality rates.1 According to the World Cancer Research Fund, HCC is the sixth most frequently diagnosed cancer worldwide and the third leading cause of cancerrelated deaths.2 HCC typically develops in the context of  \nchronic liver inflammation, most often as a consequence of persistent hepatitis B or C virus infection. These ongoing inflammatory processes progressively drive hepatic fibrosis and cirrhosis, establishing a pathological environment conducive to malignant transformation.3 The pathogenesis of HCC is highly complex, involving multiple molecular pathways and the gradual accumulation of genetic and epigenetic alterations, which together give rise to a heterogeneous mutational landscape.  \nCorresponding author : Ankur Sharma  \nTranslational Genomics Program, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst NSW 2010, Australia Tel: +61-2893555752, Fax: +610293555752, E-mail: [ankur.sharma@garvan.org.au](ankur.sharma@garvan.org.au)  \n[https://orcid.org/0000-0002-6862-136X](https://orcid.org/0000-0002-6862-136X)  \nEditor: Terence Kin Wah Lee, The Hong Kong Polytechnic University, Hong Kong Received : Dec. 12, 2025 / Revised : Feb. 26, 2026 / Accepted : Feb. 26, 2026  \nCopyright © 2026 by Korean Association for the Study of the Liver  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/3.0/](http://creativecommons.org/licenses/by-nc/3.0/)) which permits unrestricted non-commercial use, dist","cbCaiuw0Q7duT49D","https://ap.wps.com/l/cbCaiuw0Q7duT49D","pdf",3823453,27,"English","# Introduction\n## Oncofetal ecosystem and immune evasion\n# Therapeutic strategies targeting oncofetal dependencies\n## Vaccine platforms and mRNA–lipid nanoparticle vaccines\n## Combinations with immune checkpoint inhibitors\n# Challenges for effective oncofetal-directed therapy\n## Overcoming liver tolerance and antigenic heterogeneity","[{\"question\":\"What is oncofetal reprogramming in hepatocellular carcinoma?\",\"answer\":\"HCC tumours can reactivate developmental programs, creating an oncofetal ecosystem characterized by re-expression of foetal antigens and foetal-like stromal and immune subsets.\"},{\"question\":\"How does the oncofetal ecosystem affect immunotherapy outcomes?\",\"answer\":\"Oncofetal features promote immune evasion and shape therapeutic response in the clinic, contributing to variability in immunotherapy effectiveness.\"},{\"question\":\"Which vaccine approaches are highlighted as promising in this review?\",\"answer\":\"The review highlights emerging vaccine platforms, with a particular emphasis on mRNA–lipid nanoparticle vaccines designed to induce robust, durable antitumour immunity.\"}]","Oncofetal reprogramming in hepatocellular carcinoma - linking developmental programs to cancer vaccines and immunotherapy | PDF",1790120120,68,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e31f282b46f9271e87bc6022d54f0ff2.webp",983,1318,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c23395cd14d0d3c0050239178c9f5c2.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0108fa42d6c5f4f61f3f4af93b51734.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eaddd21f291af1cca12555a3c962bc11.webp",980,1306]